title: [Antiangiogenic agents: current limits in thoracic oncology].
abstract: Antiangiogenic agents appear as major therapeutic options in renal, colorectal and breast cancer. Their part in thoracic oncology is still limited today except for bevacizumab. We review the current limits of antiangiogenic agents in terms of efficacy, activity, tolerance and therapeutic strategies. Problems about predictive biomarkers and cost-effectiveness of antiangiogenic agents in thoracic oncology are also mentioned.
authors.affiliation: CLCC Oscar-Lambret, département de cancérologie générale, Lille Cedex, France. e-dansin@o-lambret.fr
authors.forename: Eric
authors.initials: E
authors.lastname: Dansin
authors.forename: Géraldine
authors.initials: G
authors.lastname: Lauridant
authors.forename: Bachar
authors.initials: B
authors.lastname: Chahine
mesh_terms: D000367:Age Factors; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D000068258:Bevacizumab; D015415:Biomarkers; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply* / Q000188:drug therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab